Advent Pharma Ltd. (DSE:ADVENT)
 14.30
 -0.20 (-1.38%)
  At close: Nov 3, 2025
Advent Pharma Income Statement
Financials in millions BDT. Fiscal year is July - June.
 Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year  | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 | 
|---|---|---|---|---|---|---|---|
Period Ending  | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2016 - 2019 | 
| 478.96 | 571.67 | 558.05 | 530.47 | 503.6 | 534.03 | Upgrade   | |
Revenue Growth (YoY)     | -15.79% | 2.44% | 5.20% | 5.34% | -5.70% | -11.29% | Upgrade   | 
Cost of Revenue     | 300.88 | 343.77 | 335.14 | 310.31 | 288 | 307.64 | Upgrade   | 
Gross Profit     | 178.08 | 227.9 | 222.91 | 220.16 | 215.61 | 226.39 | Upgrade   | 
Selling, General & Admin     | 82.17 | 86.26 | 87.55 | 86.78 | 79.18 | 70.98 | Upgrade   | 
Operating Expenses     | 82.17 | 86.26 | 87.55 | 86.78 | 79.18 | 70.98 | Upgrade   | 
Operating Income     | 95.91 | 141.65 | 135.36 | 133.38 | 136.42 | 155.41 | Upgrade   | 
Interest Expense     | -7.92 | -8.09 | -6.63 | -4.11 | -4.9 | -4.44 | Upgrade   | 
Interest & Investment Income     | 0.02 | 0.02 | 0.01 | 1.1 | 2.93 | 8.83 | Upgrade   | 
Other Non Operating Income (Expenses)     | -29.78 | -29.79 | -0.11 | -0.08 | 0.12 | 1.71 | Upgrade   | 
EBT Excluding Unusual Items     | 58.23 | 103.78 | 128.63 | 130.3 | 134.58 | 161.51 | Upgrade   | 
Gain (Loss) on Sale of Assets     | - | - | - | - | -0.39 | - | Upgrade   | 
Pretax Income     | 58.23 | 103.78 | 128.63 | 130.3 | 134.19 | 161.51 | Upgrade   | 
Income Tax Expense     | 9.54 | 19.79 | 29.99 | 32.76 | 20.6 | 44.45 | Upgrade   | 
Net Income     | 48.69 | 83.99 | 98.64 | 97.53 | 113.59 | 117.05 | Upgrade   | 
Net Income to Common     | 48.69 | 83.99 | 98.64 | 97.53 | 113.59 | 117.05 | Upgrade   | 
Net Income Growth     | -47.31% | -14.85% | 1.14% | -14.14% | -2.96% | -26.10% | Upgrade   | 
Shares Outstanding (Basic)     | 93 | 93 | 93 | 93 | 93 | 93 | Upgrade   | 
Shares Outstanding (Diluted)     | 93 | 93 | 93 | 93 | 93 | 93 | Upgrade   | 
EPS (Basic)     | 0.52 | 0.90 | 1.06 | 1.05 | 1.22 | 1.26 | Upgrade   | 
EPS (Diluted)     | 0.52 | 0.90 | 1.06 | 1.05 | 1.22 | 1.26 | Upgrade   | 
EPS Growth     | -47.31% | -14.85% | 1.14% | -14.14% | -2.96% | -26.10% | Upgrade   | 
Free Cash Flow     | 22.11 | 13.08 | 2.56 | -11.56 | -3.67 | -42.33 | Upgrade   | 
Free Cash Flow Per Share     | 0.24 | 0.14 | 0.03 | -0.12 | -0.04 | -0.45 | Upgrade   | 
Dividend Per Share     | 0.100 | 0.100 | 0.200 | 0.200 | 0.196 | - | Upgrade   | 
Dividend Growth     | -50.00% | -50.00% | - | 1.99% | - | - | Upgrade   | 
Gross Margin     | 37.18% | 39.87% | 39.95% | 41.50% | 42.81% | 42.39% | Upgrade   | 
Operating Margin     | 20.02% | 24.78% | 24.26% | 25.14% | 27.09% | 29.10% | Upgrade   | 
Profit Margin     | 10.17% | 14.69% | 17.68% | 18.39% | 22.56% | 21.92% | Upgrade   | 
Free Cash Flow Margin     | 4.62% | 2.29% | 0.46% | -2.18% | -0.73% | -7.93% | Upgrade   | 
EBITDA     | 159.23 | 207.57 | 193.96 | 175.07 | 174.59 | 188.53 | Upgrade   | 
EBITDA Margin     | 33.25% | 36.31% | 34.76% | 33.00% | 34.67% | 35.30% | Upgrade   | 
D&A For EBITDA     | 63.32 | 65.93 | 58.6 | 41.69 | 38.17 | 33.12 | Upgrade   | 
EBIT     | 95.91 | 141.65 | 135.36 | 133.38 | 136.42 | 155.41 | Upgrade   | 
EBIT Margin     | 20.02% | 24.78% | 24.26% | 25.14% | 27.09% | 29.10% | Upgrade   | 
Effective Tax Rate     | 16.39% | 19.07% | 23.31% | 25.15% | 15.35% | 27.52% | Upgrade   | 
Advertising Expenses     | - | 0.15 | 0.19 | 0.18 | 0.15 | 0.11 | Upgrade   | 
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.